Artiva Biotherapeutics (NASDAQ:ARTV) Now Covered by Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a report released on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $20.00 target price on the stock. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q4 2024 earnings at ($0.74) EPS, FY2024 earnings at ($6.00) EPS, Q1 2025 earnings at ($0.76) EPS, Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.81) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.21) EPS, FY2026 earnings at ($0.78) EPS and FY2027 earnings at ($0.92) EPS.

Separately, Needham & Company LLC reissued a “buy” rating and set a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $21.00.

Artiva Biotherapeutics Stock Down 4.7 %

Artiva Biotherapeutics stock opened at $10.08 on Monday. The business’s fifty day moving average is $11.37. Artiva Biotherapeutics has a twelve month low of $9.68 and a twelve month high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.24). Analysts anticipate that Artiva Biotherapeutics will post -4.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new position in shares of Artiva Biotherapeutics during the third quarter valued at about $42,000. Franklin Resources Inc. purchased a new stake in Artiva Biotherapeutics during the 3rd quarter worth approximately $7,435,000. Charles Schwab Investment Management Inc. purchased a new stake in Artiva Biotherapeutics during the 3rd quarter worth approximately $623,000. Wellington Management Group LLP acquired a new position in Artiva Biotherapeutics during the 3rd quarter valued at approximately $2,912,000. Finally, Samsara BioCapital LLC purchased a new position in shares of Artiva Biotherapeutics in the third quarter worth $4,506,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.